Clinically Relevant PDX Models Resistant to CDK4/6 Inhibitors
Accelerate the development of your cyclin D-CDK4/6 pathway targeting breast cancer therapies with our latest Post-CDK4/6 Inhibitor PDX Model Screening platform. This screen features 10 rigorously validated PDX models, derived directly and established from patient tumors and maintained at a low passage to preserve molecular heterogeneity, mutation profiles, and key resistance mechanisms. This screen offers unparalleled clinical relevance, making it the ideal choice for researchers developing next-generation breast cancer treatments targeting the CDK4/6 pathway.
Clinically Relevant Models
Living bank of clinically relevant PDX models with key mutations and molecular characteristics.
Pretreated PDX Models
Established from tumor biopsies from patients pretreated with latest generation CDK4/6 therapies
Multi-omic Characterization
Clinical annotations coupled with molecular datasets and in vivo responses
Champions' Post-CDK4/6 Inhibitor PDX Model Screen includes:
-
Breast Cancer models pretreated with advanced CDK4/6 targeting therapies such as Palbociclib, Ribociclib, Abemaciclib, and more.
-
Models retaining crucial mutations of the cyclin-dependent kinase 4 and 6 (CDK4/6) pathway and mechanisms of resistance to advanced CDK4/6 therapies.
-
Complete model characterization (clinical data, NGS analysis, proteomics, phospho-proteomics, and more).
-
Several endpoint data options available including Flow Cytometry and IHC to quantify target expression and critical phenotypical changes (available upon request).
-
Terminal tumor collections for target validation are available upon request (Snap Frozen/FFPE).
-
No minimum to enroll & 50% off a Standard of Care Agent arm (selected by Champions).
